Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Active not recruiting 4Unknown 2Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 2Endometrial Neoplasms 2Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 6Carboplatin 6Radiotherapy 5olaparib 4Surveys and Questionnaires 4Cisplatin 4Surgical Procedures, Operative 3Sentinel Lymph Node Biopsy 3Metformin 3pembrolizumab 2lenvatinib 2durvalumab 2dostarlimab 2anlotinib 2Reverse Transcriptase Polymerase Chain Reaction 2Progesterone 2Magnetic Resonance Spectroscopy 2Injections 2High-Energy Shock Waves 2Hematologic Tests 2Genetic Testing 2Docetaxel 2Blood Specimen Collection 2Base Sequence 2Amplified Fragment Length Polymorphism Analysis 2vistusertib 1serabelisib 1pazopanib 1palbociclib 1onapristone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Endometrial Neoplasms × dostarlimab × Clear all
NCT05728814 2024-02-23

DORA

Grupo Español de Investigación en Cáncer de Ovario

Unknown
100 enrolled
Gynecologic

Endometrial Neoplasms

NCT03016338 2024-01-30

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

University Health Network, Toronto

Phase 2 Unknown
51 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡